Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era?

Jagadeesh Bayry, Sébastien Lacroix-Desmazes, Michel D. Kazatchkine, Srini V. Kaveri

Sortida de recerca: Article

71 Cites (Scopus)

Resum

The dramatic increase in both the number of novel infectious agents and resistance to antimicrobial drugs has incited the need for adjunct therapies in the war against infectious diseases. Exciting recent studies have demonstrated the use of antibodies in the form of intravenous immunoglobulin (IVIg) against infections. By virtue of the diverse repertoire of immunoglobulins that possess a wide spectrum of antibacterial and antiviral specificities, IVIg provides antimicrobial efficacy independently of pathogen resistance and represents a promising alternative strategy for the treatment of diseases for which a specific therapy is not yet available.
Idioma originalEnglish
RevistaTrends in Pharmacological Sciences
Volum25
Número d'incidència6
DOIs
Estat de la publicacióPublished - 1 de gen. 2004

Empremta digital Navegar pels temes de recerca de 'Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era?'. Junts formen una empremta única.

  • Citeu això